Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel Followed by Provenge in Castration-Resistant Prostate Cancer

NCT02793765 is registered in ClinicalTrials.gov with The University of Texas Health Science Center, Houston as lead sponsor.

NCT NCT02793765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02793765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel Followed by Provenge in Castration-Resistant Prostate Cancer
Lead sponsor
The University of Texas Health Science Center, Houston
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2016
Completion date
July 31, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer